Efficacy and Safety of Anlotinib in Patients with Advanced Non-Small Cell Lung Cancer: A Real-World Study

BACKGROUND: Anlotinib is a multi-target tyrosine kinase inhibitor (TKI) independently developed by China, which can inhibit tumor angiogenesis and tumor cell proliferation. The ALTER 0303 study has suggested that anlotinib improved overall survival (OS) and progression-free survival (PFS) in the tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhong, Qiuxia, Liu, Zhihua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149213/
https://www.ncbi.nlm.nih.gov/pubmed/34045898
http://dx.doi.org/10.2147/CMAR.S304838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8149213/
https://www.ncbi.nlm.nih.gov/pubmed/34045898
http://dx.doi.org/10.2147/CMAR.S304838

Ejemplares similares